Covered recipient · General Payments record
MARTIN S MARON
Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease
General Payments · PY2019–2025
$89,785.75
- Reported across 52 records
- CMS publication 2026-06-30
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2025 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $14,170.00 | 5 |
| Food and Beverage | $369.13 | 4 |
By paying entity
PY2025 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Amicus Therapeutics, Inc. | $7,180.00 | 1 |
| Alexion Pharmaceuticals, Inc. | $3,902.30 | 3 |
| Novo Nordisk AS | $3,140.00 | 2 |
| BOSTON SCIENTIFIC CORPORATION | $128.50 | 1 |
| GENZYME CORPORATION | $94.18 | 1 |
| E.R. Squibb & Sons, L.L.C. | $94.15 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2025 (9)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Alexion Pharmaceuticals, Inc. | $700.00 | 10/27/2025 | Consulting Fee | Undisputed | 06/30/2026 | 1202951872 | CMS |
| Alexion Pharmaceuticals, Inc. | $52.30 | 11/07/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1202914740 | CMS |
| Alexion Pharmaceuticals, Inc. | $3,150.00 | 11/10/2025 | Consulting Fee | Undisputed | 06/30/2026 | 1202921288 | CMS |
| Amicus Therapeutics, Inc. | $7,180.00 | 12/10/2025 | Consulting Fee | Undisputed | 06/30/2026 | 1252321709 | CMS |
| Boston Scientific Corporation | $128.50 | 02/21/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1181187982 | CMS |
| E.R. Squibb & Sons, L.L.C. | $94.15 | 05/06/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1184948344 | CMS |
| GENZYME CORPORATION | $94.18 | 11/07/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1233374918 | CMS |
| Novo Nordisk AS | $1,962.50 | 09/01/2025 | Consulting Fee | Undisputed | 06/30/2026 | 1189186743 | CMS |
| Novo Nordisk AS | $1,177.50 | 09/01/2025 | Consulting Fee | Undisputed | 06/30/2026 | 1189187021 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.